91 related articles for article (PubMed ID: 8212244)
1. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression.
Hess AD; Fischer AC; Horwitz LR; Laulis MK
Transplant Proc; 1993 Oct; 25(5):2811-3. PubMed ID: 8212244
[No Abstract] [Full Text] [Related]
2. Cyclosporine-induced syngeneic graft-versus-host disease: recognition of self MHC class II antigens in vivo.
Hess AD; Horwitz LR; Laulis MK
Transplant Proc; 1993 Feb; 25(1 Pt 2):1218-21. PubMed ID: 8442094
[No Abstract] [Full Text] [Related]
3. Kinetics of inducer/effector cell generation in the thymus in cyclosporine-induced autoimmunity.
Wodzig KW; Majoor GD; van Breda Vriesman PJ
Transplant Proc; 1993 Oct; 25(5):2819-21. PubMed ID: 8212247
[No Abstract] [Full Text] [Related]
4. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
Hess AD; Thoburn CJ
Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
[TBL] [Abstract][Full Text] [Related]
5. Immunological mechanisms governing tolerance to self-major histocompatibility complex antigens after bone marrow transplantation.
Hess AD; Fischer AC; Horwitz LR; Bright EC; Hess JM
Transplant Proc; 1995 Feb; 27(1):1370-3. PubMed ID: 7878915
[No Abstract] [Full Text] [Related]
6. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
Thoburn CJ; Miura Y; Bright EC; Hess AD
Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
[TBL] [Abstract][Full Text] [Related]
7. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
Hess AD; Thoburn CJ; Chen W; Bright AE
Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine preferentially inhibits clonal deletion of CD8-positive T cells with an MHC class II restricted autoreactive T-cell receptor.
Severino ME; Laulis MK; Horwitz LR; Hess AD
Transplant Proc; 1993 Feb; 25(1 Pt 1):520-3. PubMed ID: 8438399
[No Abstract] [Full Text] [Related]
9. Antigen-specific T-lymphocyte responses in acute and chronic syngeneic graft-versus-host disease.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Transplant Proc; 2005; 37(1):53-6. PubMed ID: 15808545
[TBL] [Abstract][Full Text] [Related]
10. A two-phase pathogenesis of graft-versus-host disease in mice.
van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune-mediated vasculopathy.
Chen W; Thoburn CJ; Miura Y; Sommer M; Hruban R; Qian Z; Baldwin W; Hess AD
Clin Immunol; 2001 Jul; 100(1):57-70. PubMed ID: 11414746
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
Chen W; Thoburn C; Hess AD
J Immunol; 1998 Dec; 161(12):7040-6. PubMed ID: 9862741
[TBL] [Abstract][Full Text] [Related]
13. Malignant neoplasms in cyclosporine-induced autoimmunity.
Wodzig KW; Majoor GD; Tiebosch AT; de Heer E; van Breda Vriesman PJ
Transplant Proc; 1993 Oct; 25(5):2816-8. PubMed ID: 8212246
[No Abstract] [Full Text] [Related]
14. Effect of posttransplant cyclosporine treatment on the development of syngeneic GVHD in recipients of UV-B irradiated bone marrow cells.
Ohajekwe OA; Hardy MA; Oluwole SF
Transplant Proc; 1995 Feb; 27(1):1385. PubMed ID: 7878922
[No Abstract] [Full Text] [Related]
15. Autologous graft-versus-host disease: a new frontier in immunotherapy.
Hess AD; Jones RJ; Morris LE; Noga SJ; Yeager AM; Vogelsang GB; Santos GW
Bone Marrow Transplant; 1992; 10 Suppl 1():16-21. PubMed ID: 1521086
[No Abstract] [Full Text] [Related]
16. Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models.
Bos GM; Majoor GD; Slaaf DW; van de Gaar MJ; Weijmer-van Velzen JS; van Breda Vriesman PJ
Transplant Proc; 1989 Apr; 21(2):3262-3. PubMed ID: 2652812
[No Abstract] [Full Text] [Related]
17. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.
Jäger MD; Liu JY; Timrott KF; Popp FC; Stoeltzing O; Lang SA; Piso P; Geissler EK; Schlitt HJ; Dahlke MH
Exp Hematol; 2007 Jan; 35(1):164-70. PubMed ID: 17198885
[TBL] [Abstract][Full Text] [Related]
18. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
Sykes M; Abraham VS; Harty MW; Pearson DA
Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
[No Abstract] [Full Text] [Related]
20. T-cell development and susceptibility to cyclosporine A-induced autoimmunity in MHC-matched bone marrow/thymus chimeras.
Damoiseaux J; van de Gaar J; van der Heijden H; van Breda Vriesman P
Transplant Proc; 1999 May; 31(3):1579-80. PubMed ID: 10331009
[No Abstract] [Full Text] [Related]
[Next] [New Search]
